These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 17826691)

  • 21. Preclinical predictors of clinical safety: opportunities for improvement.
    Sistare FD; DeGeorge JJ
    Clin Pharmacol Ther; 2007 Aug; 82(2):210-4. PubMed ID: 17507920
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Screening for reactive intermediates and toxicity assessment in drug discovery.
    Caldwell GW; Yan Z
    Curr Opin Drug Discov Devel; 2006 Jan; 9(1):47-60. PubMed ID: 16445117
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Boxed warnings and other FDA communication tools.
    Marks NS; Weiss K
    Am Fam Physician; 2010 Feb; 81(3):259. PubMed ID: 20112882
    [No Abstract]   [Full Text] [Related]  

  • 24. Preclinical assessment of drug-induced proarrhythmias: role of the arterially perfused rabbit left ventricular wedge preparation.
    Wang D; Patel C; Cui C; Yan GX
    Pharmacol Ther; 2008 Aug; 119(2):141-51. PubMed ID: 18423604
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drugs and biologics in pregnancy and breastfeeding: FDA in the 21st century.
    Kweder SL
    Birth Defects Res A Clin Mol Teratol; 2008 Sep; 82(9):605-9. PubMed ID: 18704917
    [No Abstract]   [Full Text] [Related]  

  • 26. High drug attrition rates--where are we going wrong?
    Hutchinson L; Kirk R
    Nat Rev Clin Oncol; 2011 Mar; 8(4):189-90. PubMed ID: 21448176
    [No Abstract]   [Full Text] [Related]  

  • 27. Future of toxicology--mechanisms of toxicity and drug safety: where do we go from here?
    Stevens JL
    Chem Res Toxicol; 2006 Nov; 19(11):1393-401. PubMed ID: 17112225
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regulatory immunotoxicology: does the published evidence support mandatory nonclinical immune function screening in drug development?
    Snodin DJ
    Regul Toxicol Pharmacol; 2004 Dec; 40(3):336-55. PubMed ID: 15546688
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk evaluation and mitigation strategies for drugs with abuse liability: public interest, special interest, conflicts of interest, and the industry perspective.
    Wright C; Schnoll S; Bernstein D
    Ann N Y Acad Sci; 2008 Oct; 1141():284-303. PubMed ID: 18991964
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current challenges in the evaluation of cardiac safety during drug development: translational medicine meets the Critical Path Initiative.
    Piccini JP; Whellan DJ; Berridge BR; Finkle JK; Pettit SD; Stockbridge N; Valentin JP; Vargas HM; Krucoff MW;
    Am Heart J; 2009 Sep; 158(3):317-26. PubMed ID: 19699852
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Finding value in the U.S. Food and Drug Administration's Fast Track program.
    Reichert JM; Rochon SL; Zhang BD
    Drug News Perspect; 2009; 22(1):53-8. PubMed ID: 19209299
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Black box warnings-implications in practice.
    Zarowitz BJ
    Geriatr Nurs; 2008; 29(6):402-9. PubMed ID: 19064138
    [No Abstract]   [Full Text] [Related]  

  • 33. Leveraging exploratory investigational new drug studies to accelerate drug development.
    Jacobson-Kram D; Mills G
    Clin Cancer Res; 2008 Jun; 14(12):3670-4. PubMed ID: 18559581
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Information from your family doctor. Drug warnings: is my medicine safe?
    Am Fam Physician; 2010 Feb; 81(3):304. PubMed ID: 20128116
    [No Abstract]   [Full Text] [Related]  

  • 35. A critical evaluation of in vitro cell culture models for high-throughput drug screening and toxicity.
    Astashkina A; Mann B; Grainger DW
    Pharmacol Ther; 2012 Apr; 134(1):82-106. PubMed ID: 22252140
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Critical Path to New Medicines: data sharing.
    Altern Lab Anim; 2006 Jun; 34(3):273-4. PubMed ID: 16874922
    [No Abstract]   [Full Text] [Related]  

  • 37. The impact of molecular biology on drug discovery.
    Belfield GP; Delaney SJ
    Biochem Soc Trans; 2006 Apr; 34(Pt 2):313-6. PubMed ID: 16545102
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of Food and Drug Administration warnings on antidepressant use in a national sample.
    Olfson M; Marcus SC; Druss BG
    Arch Gen Psychiatry; 2008 Jan; 65(1):94-101. PubMed ID: 18180433
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-throughput human metabolism and toxicity analysis.
    Lee MY; Dordick JS
    Curr Opin Biotechnol; 2006 Dec; 17(6):619-27. PubMed ID: 17046235
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improving the decision-making process in structural modification of drug candidates: reducing toxicity.
    Nassar AE; Kamel AM; Clarimont C
    Drug Discov Today; 2004 Dec; 9(24):1055-64. PubMed ID: 15582794
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.